Brain

FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair

HOUSTON, April 02, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued…

2 weeks ago

Experience Onward Partners with Enthea to Expand Access to Psilocybin Treatment Through a Medical Tourism Benefit

Portland, Oregon--(Newsfile Corp. - April 2, 2025) - Experience Onward, Oregon's premier state-licensed psilocybin service center, is proud to announce…

2 weeks ago

Wellform MD is first in Iowa to Offer Leading-edge Technology Using Brain Stimulation to Treat Depression

Complimentary Launch Party April 24 to Showcase New Procedure ANKENY, Iowa, April 1, 2025 /PRNewswire/ -- Wellform MD, Des Moine's…

2 weeks ago

Leading Mental Health Provider SonderMind Expands Nationwide, Delivering High-Quality Mental Health Care in All 50 States

DENVER, April 1, 2025 /PRNewswire/ -- SonderMind, a leader in comprehensive, personalized mental health care, announced it is now serving…

2 weeks ago

Preventing Underage Drinking Starts at Home: Talk It Out NC Empowers Parents and Children to Take Action Against Underage Drinking

Alcohol Awareness Month Highlights the Importance of Open Dialogue to Prevent Underage Drinking RALEIGH, N.C., April 1, 2025 /PRNewswire/ -- Talk…

2 weeks ago

REMINDER: Microbot Medical Announces Data from the Company’s ACCESS-PVI trial will be Presented via Podium Presentation at Society of Interventional Radiology Annual Meeting

Company Reaffirms Expected Timing of FDA Decision With Respect to 510(K) Clearance of LIBERTY® During the Current Second QuarterBRAINTREE, Mass.,…

2 weeks ago

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

– Initial data readout on track for second half of 2025 HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech,…

2 weeks ago

Cerevance Presents Topline Results from Phase 2 ASCEND Trial of Solengepras as Monotherapy Treatment for Early-Stage Parkinson’s Disease at AD/PD 2025

Solengepras showed evidence of potential benefit in functional and non-motor symptoms versus placebo as measured by MDS-UPRDS Parts I, II,…

2 weeks ago

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Data published in Neuro-Oncology demonstrate promising safety profile and potential survival benefit when combining CAN-2409 and nivolumab with standard of…

2 weeks ago